Johnson & Johnson will pay the state of Oregon $4 million in a new DePuy ASR metal-on-metal hip replacement lawsuit settlement. The Oregon Department of Justice alleged that DePuy knowingly marketed and sold metal hip replacements that were prone to failure. DePuy sold 432 of the ASR XL hip replacement devices in Oregon.
Stryker Corporation has brought an anti-trust case against rival orthopedic manufacturer Medtronic over potential patent infringement, despite both companies facing lawsuits for their faulty products. Stryker is facing multiple lawsuits alleging that its hip replacements caused injuries, while Medtronic is facing lawsuits alleging that its bone graft system caused injuries.
DePuy has waived its “walk-away rights” in a hip replacement settlement and will pay more than $2.5 billion to thousands of patients who were injured by DePuy ASR hip replacements. The decision to waive the rights means the company acknowledged that enough patients have agreed to the settlement.
Doctors have seen a rise in pseudotumors and complications from pseudotumors among patients who received faulty metal-on-metal hip replacements. The painful inflammatory lesions have been linked to the Wright Conserve Plus Total Hip Resurfacing System, along with other hip replacement side effects.
Stryker Corporation is facing an increasing number of hip replacement lawsuits alleging that the company’s implants were defective and caused injuries. More than 500 Stryker lawsuits allege that the metal components of the Rejuvenate and ABG II modular hip replacements can lead to corrosion, fretting and other severe complications.
Nearly 100,000 patients who received a DePuy ASR hip replacement device were victims of the device manufacturer failing to take action, according to an investigative report by the Australian Broadcasting Corporation. According to the report, employees within Johnson & Johnson, the parent company of manufacturer DePuy Orthopaedics, admitted the implants were faulty.
A retroactive study of patients who ended up having severe complications from their metal-on-metal hip replacements showed early blood tests could predict eventual failure. Patients who had a higher concentration of cobalt in their blood were much more likely to eventually require revision surgery to remove the device.